Literature DB >> 3771594

An investigation into the mechanisms of the cardiovascular effects of 5-hydroxytryptamine in conscious normotensive and DOCA-salt hypertensive rats.

D W Dalton, W Feniuk, P P Humphrey.   

Abstract

The actions of intravenously administered 5-hydroxytryptamine (5-HT) have been analysed in conscious DOCA-salt hypertensive rats using selective 5-HT receptor agonists and antagonists to determine the receptor mechanisms involved and to compare them with those in conscious normotensive rats. In both normotensive and hypertensive rats 5-HT, 3 and 10 micrograms i.v., produced a complex triphasic effect on blood pressure consisting of an initial short lasting depressor response, which was followed by a pressor response and then, finally, a hypotensive phase. Marked decreases in heart rate were observed immediately after dosing, which were followed by small increases in rate. The selective 5-HT3-receptor agonist, 2-methyl 5-HT, 3-30 micrograms i.v., produced immediate and marked dose-related decreases in blood pressure and heart rate in both normotensive and DOCA-salt hypertensive rats. The 5-HT3-receptor antagonist, MDL 72222, 0.03 and 0.1 mg/kg i.v., antagonised these effects in both normotensive and DOCA-salt hypertensive rats. Treatment with MDL 72222, 0.3 mg/kg i.v., abolished the initial depressor response and bradycardia produced by 5-HT. The 5-HT2 receptor agonist, alpha-methyl 5-HT, 3-30 micrograms i.v., produced dose-related increases in blood pressure which were significantly greater in magnitude in DOCA-salt hypertensive than normotensive rats. Bradycardia was observed consistently at 30 micrograms only. The 5-HT 2 receptor antagonist, ketanserin, 0.03-0.3 mg/kg i.v., caused a dose-dependent antagonism of the pressor responses produced by alpha-methyl 5-HT, but had no effect on the increases in blood pressure produced by angiotensin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3771594     DOI: 10.1111/j.1474-8673.1986.tb00648.x

Source DB:  PubMed          Journal:  J Auton Pharmacol        ISSN: 0144-1795


  8 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

Review 2.  5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.

Authors:  Stephanie W Watts; Robert Patrick Davis
Journal:  Cardiovasc Ther       Date:  2011-02       Impact factor: 3.023

3.  5-HT causes splanchnic venodilation.

Authors:  Bridget M Seitz; Hakan S Orer; Teresa Krieger-Burke; Emma S Darios; Janice M Thompson; Gregory D Fink; Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

4.  5-HT does not lower blood pressure in the 5-HT7 knockout rat.

Authors:  Bridget M Seitz; Elena Y Demireva; Huirong Xie; Gregory D Fink; Teresa Krieger-Burke; William M Burke; Stephanie W Watts
Journal:  Physiol Genomics       Date:  2019-05-24       Impact factor: 3.107

5.  Comparative analysis of two types of 5-hydroxytryptamine receptor mediating vasorelaxation: differential classification using tryptamines.

Authors:  G R Martin; P Leff; D Cambridge; V J Barrett
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-10       Impact factor: 3.000

6.  5-HT7 Receptor Restrains 5-HT-induced 5-HT2A Mediated Contraction in the Isolated Abdominal Vena Cava.

Authors:  Romina Gonzalez-Pons; Kiera McRae; Janice M Thompson; Stephanie W Watts
Journal:  J Cardiovasc Pharmacol       Date:  2021-08-01       Impact factor: 3.271

7.  5-HT is a potent relaxant in rat superior mesenteric veins.

Authors:  Stephanie W Watts; Emma S Darios; Bridget M Seitz; Janice M Thompson
Journal:  Pharmacol Res Perspect       Date:  2015-01-05

8.  Reduction in Hindquarter Vascular Resistance Supports 5-HT7 Receptor Mediated Hypotension.

Authors:  Bridget M Seitz; Stephanie W Watts; Gregory D Fink
Journal:  Front Physiol       Date:  2021-06-24       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.